Canopy Growth's German Subsidiary Teams Up With Portugal's Gro-Vida To Expand Medical Cannabis Supply

Portugal-based medical marijuana grower Gro-Vida teamed up with Canopy Growth Germany GmbH, a subsidiary of cannabis giant Canopy Growth Corporation CGC. This agreement is a key step for Gro-Vida to position itself in Germany’s growing medical marijuana market while supporting Canopy Growth GmbH’s strategy of securing EU-based supply through an asset-light approach in addition to existing supply from the company's Canadian GMP production platform.

"We are incredibly proud to be working with Canopy Growth Germany," stated Mallory Bodnar, managing director at Gro-Vida. "It is a remarkable honor to have a global leader recognize the exceptional quality of cannabis produced here in Portugal. This is not only a testament to our hard work but points to the promising future of Portuguese-grown cannabis on the world stage."

Read Also: Tilray Joins German Cannabis Fiesta With First Locally Grown Strains

Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

The supply agreement represents an opportunity to drive growth for both companies, blending Gro-Vida's cultivation expertise and EU-GMP production partnerships with Canopy Growth GmbH's extensive network and in-market expertise. Under the terms of the supply agreement, Gro-Vida will cultivate a range of exclusive medicinal cannabis flower for Canopy Growth GmbH, with the products slated for release under the Tweed brand.

Tara Rozalowsky, chief growth officer and president, International, Canopy Growth, says this move is part of the company's larger plans for international expansion. "Part of our global strategy is ensuring a diverse and high-quality supply chain, and Gro-Vida is an important piece of this strategy. Sourcing EU-GMP flower from Portugal, alongside our EU-GMP Canadian-grown cannabis flower, allows us to offer a versatile and competitive product portfolio in the German market while advancing our asset light strategy for growth."

Products will be available via prescription and can be requested by patients nationwide in Germany from their healthcare practitioner beginning in calendar Q1 of 2025.

Cannabis In Germany

A recent report on Germany’s cannabis market by Prohibition Partners revealed that German medical marijuana sales are projected to reach €420 million in 2024 ($260.66 million) reaching €1 billion by 2028.

The report comes several months after major cannabis reform in Germany with the implementation of the Cannabis Act (CanG) and the associated MedCanG Act. Partial cannabis legalization took effect in Germany on April 1, allowing people over 18 to legally possess up to 25 grams of dried cannabis and cultivate up to three plants at home. One of the biggest breakthroughs under the law is that medical cannabis is essentially regulated like ibuprofen.

Price Action

Canopy Growth shares closed Friday's market session 1.04% higher at $3.9 per share.

Read Next:

• German Cannabis: 20 Tons, 10M Grams – And That’s Only 0.3% Of The Market, What’s Missing?

Photo: Courtesy of OMfotovideocontent on Shutterstock